Lyra Therapeutics, Inc. (OTCPK: LYRA)
Health Care · Pharmaceuticals · US
$0.01
-96.00% today · -99.9% 1Y
Lyra Therapeutics, Inc. (OTCPK: LYRA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $17.75K and employs 27 people.
Over the last twelve months the share price has lost 99.9%, trading between 0.00 and 8.75.
Tweenvest scores Lyra Therapeutics, Inc. across four factors: quality 10/100, value 51/100. Its strongest factor is value.
LYRA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.75K
- Revenue (TTM)
- $398.00K
- P/E
- —
- EPS
- -18.62
- Dividend yield
- —
- Beta (5Y)
- 0.71
- 52-week high
- $8.75
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.77M
- Employees
- 27
- Next earnings
- —
About Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.
- ISIN
- US55234L2043
- Founded
- 2005
- Listed since
- May 1, 2020
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.35 | +0.16% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.